Filling the gaps in the global prevalence map of clinical antimicrobial resistance

  06 January 2021

While antimicrobial resistance is an urgent global problem, substantial clinical surveillance gaps exist in low- and middle-income countries (LMICs). We fill the gaps in the global prevalence map of nine pathogens, resistant to 19 (classes of) antibiotics (representing 75 unique combinations), based on the robust correlation between countries’ socioeconomic profiles and extensive surveillance data. Our estimates for carbapenem-resistant Acinetobacter baumannii and third-generation cephalosporin-resistant Escherichia coli benefit over 2.2 billion people in countries with currently insufficient diagnostic capacity. We show how structural surveillance investments can be prioritized based on the magnitude of prevalence estimated (Middle Eastern countries), the relative prevalence increase over 1998 to 2017 (sub-Saharan African countries), and the improvement of model performance achievable with new surveillance data (Pacific Islands).

Further reading: PNAS
Author(s): Rik Oldenkamp,, Constance Schultsz, Emiliano Mancini, Antonio Cappuccio
Effective Surveillance  
Back

OUR UNDERWRITERS

Unrestricted financial support by:

LifeArc

Antimicrobial Resistance Fighter Coalition

Bangalore Bioinnovation Centre

INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS





Ambassador Network

Join the AMR Insights Ambassador Network today!

Connect to over 650 AMR professionals and students in 65 countries!

Register

What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!

Keep me informed